Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK + subtypes

Blood

Volumn 109, Issue 5, 2007, Pages 2156-2164

  Lamant, Laurence ^a,b   De Reyniès, Aurélien ^c   Duplantier, Marie Michèle ^a,b   Rickman, David S ^c   Sabourdy, Frédérique ^a,b   Giuriato, Sylvie ^a,b   Brugières, Laurence ^d   Gaulard, Philippe ^e   Espinos, Estelle ^a,b   Delsol, Georges ^a,b,f  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c Center de Recherche des Cordeliers   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CCAAT ENHANCER BINDING PROTEIN BETA; CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 21; INTERLEUKIN 22; PROTEIN BCL 6; PROTEIN TYROSINE PHOSPHATASE; SERINE PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER RELAPSE; CANCER STAGING; CHILD; CLINICAL ARTICLE; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MALE; MICROARRAY ANALYSIS; MORPHOLOGY; PRIORITY JOURNAL;

EID: 33847406330     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-06-028969     Document Type: Article

References (65)

1. Delsol G, Ralfkiaer E, Stein H, Wright D, Jaffe ES. Anaplastic large cell lymphoma: primary systemic (T/null cell type). In: Jaffe ES, Harris NL, Stein H, eds. World Health Organization (WHO) Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:230-235.
2. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-3695.
3. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263:1281-1284.
4. Pulford K, Lamant L, Espinos E, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 2004;61:2939-2953.
5. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91:2076-2084.
6. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913-3921.
7. Brugieres L, Deley MC, Pacquement H, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92:3591-3598.
8. Colleoni GW, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M. ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol. 2000;156:781-789.
9. Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood. 1999;93:3088-3095.
10. Lamant L, Gascoyne RD, Duplantier MM, et al. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer. 2003;37:427-432.
11. Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood. 1988;72:234-240.
12. Epstein AL, Kaplan HS. Biology of the human malignant lymphomas, I: establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas. Cancer. 1974;34:1851-1872.
13. Lamant L, Espinos E, Duplantier M, et al. Establishment of a novel anaplastic large-cell lymphoma-cell line (COST) from a "small-cell variant" of ALCL. Leukemia. 2004;18:1693-1698.
14. del Mistro A, Leszl A, Bertorelle R, et al. A CD30-positive T cell line established from an aggressive anaplastic large cell lymphoma, originally diagnosed as Hodgkin's disease. Leukemia. 1994;8:1214-1219.
15. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
16. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249-264.
17. Robinson D, Foulds L. Comparison of phylogenetic trees. Math Biosci. 1981;53:131-147.
18. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics. 2003;19:368-375.
19. Al-Shahrour F, Diaz-Uriarte R, Dopazo J. FatiGO: a web tool for finding significant associations of Gene Ontology terms with groups of genes. Bioinformatics. 2004;20:578-580.
20. Liang Y, Zhou Y, Shen P. NF-κB and its regulation on the immune system. Cell Mol Immunol. 2004;1:343-350.
21. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
22. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
23. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
24. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991-9996.
25. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105:3671-3678.
26. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851-862.
27. Rosenwald A. DNA microarrays in lymphoid malignancies. Oncology (Williston Park). 2003;17:1743-1748; discussion 1750, 1755, 1758-1749 passim.
28. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
29. Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2004;199:59-68.
30. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159-2169.
31. Abraham RS, Ballman KV, Dispenzieri A, et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood. 2005;105:794-803.
32. Martinez-Delgado B, Melendez B, Cuadros M, et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res. 2004;10:4971-4982.
33. Thompson MA, Stumph J, Henrickson SE, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol. 2005;36:494-504.
34. Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006;25:1560-1570.
35. Martinez-Delgado B, Cuadros M, Honrado E, et al. Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas. Leukemia. 2005;19:2254-2263.
36. Fillmore GC, Lin Z, Bohling SD, et al. Gene expression profiling of cell lines derived from T-cell malignancies. FEBS Lett. 2002;522:183-188.
37. Li S, Ross DT, Kadin ME, Brown PO, Wasik MA. Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray. Am J Pathol. 2001;158:1231-1237.
38. Wellmann A, Thieblemont C, Pittaluga S, et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 2000;96:398-404.
39. + anaplastic large-cell lymphomas. Blood. 1997;90:2445-2450.
40. Kerl K, Vonlanthen R, Nagy M, et al. Alterations on the 5′ noncoding region of the BCL-6 gene are not correlated with BCL-6 protein expression in T cell non-Hodgkin lymphomas. Lab Invest. 2001;81:1693-1702.
41. Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science. 1993;262:747-750.
42. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
43. Chtanova T, Tangye SG, Newton R, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol. 2004;173:68-78.
44. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490-494.
45. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000;13:199-212.
46. Takekawa M, Itoh F, Hinoda Y, et al. Cloning and characterization of a human cDNA encoding a novel putative cytoplasmic protein-tyrosine-phosphatase. Biochem Biophys Res Commun. 1992;189:1223-1230.
47. Cong F, Spencer S, Cote JF, et al. Cytoskeletal protein PSTPIP1 directs the PEST-type protein tyrosine phosphatase to the c-Abl kinase to mediate Abl dephosphorylation. Mol Cell. 2000;6:1413-1423.
48. Honorat JF, Ragab A, Lamant L, Delsol G, Ragab-Thomas J. SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood. 2006;107:4130-4138.
49. Perlmutter DH, Cole FS, Kilbridge P, Rossing TH, Colten HR. Expression of the alpha 1-proteinase inhibitor gene in human monocytes and macrophages. Proc Natl Acad Sci U S A. 1985;82:795-799. 50. Isaacson P, Wright DH. Malignant histiocytosis of the intestine: its relationship to malabsorption and ulcerative jejunitis. Hum Pathol. 1978;9:661-677.
50. Isaacson PG, O'Connor NT, Spencer J, et al. Malignant histiocytosis of the intestine: a T-cell lymphoma. Lancet. 1985;2:688-691.
51. Villalva C, Trempat P, Greenland C, et al. Isolation of differentially expressed genes in NPMALK-positive anaplastic large cell lymphoma. Br J Haematol. 2002;118:791-798.
52. Chawla RK, Lawson DH, Sarma PR, Nixon DW, Travis J. Serum alpha-1 proteinase inhibitor in advanced cancer: mass variants and functionally inert forms. Cancer Res. 1987;47:1179-1184.
53. Harris CC, Primack A, Cohen MH. Elevated alpha1-antitrypsin serum levels in lung cancer patients. Cancer. 1974;34:280-281.
54. Laine A, Leroy A, Hachulla E, Davril M, Dessaint JP. Comparison of the effects of purified human alpha 1-antichymotrypsin and alpha 1-proteinase inhibitor on NK cytotoxicity: only alpha 1-proteinase inhibitor inhibits natural killing. Clin Chim Acta. 1990;190:163-173.
55. Lejeune PJ, Mallet B, Farnarier C, Kaplanski S. Changes in serum level and affinity for concanavalin A of human alpha 1-proteinase inhibitor in severe burn patients: relationship to natural killer cell activity. Biochim Biophys Acta. 1989;990:122-127.
56. Okumura Y, Kudo J, Ikuta T, Kurokawa S, Ishibashi H, Okubo H. Influence of acute-phase proteins on the activity of natural killer cells. Inflammation. 1985;9:211-219.
57. Jundt F, Raetzel N, Muller C, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein and NF-κB activity in Hodgkin and anaplastic large cell lymphomas. Blood. 2005;106:1801-1807.
58. McKnight SL. McBindall - a better name for CCAAT/enhancer binding proteins? Cell. 2001;107:259-261.
59. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 2002;365:561-575.
60. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev. 2006;16:51-59.
61. Chen RH, McCormick F. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells. Cancer Res. 2001;61:4445-4449.
62. Chen S, Guttridge DC, You Z, et al. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol. 2001;152:87-96.
63. Esufali S, Bapat B. Cross-talk between Rac1 GT-Pase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation. Oncogene. 2004;23:8260-8271.
64. Barker N, Morin PJ, Clevers H. The yin-yang of TCF/beta-catenin signaling. Adv Cancer Res. 2000;77:1-24.
65. Kikuchi A. Regulation of beta-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun. 2000;268:243-248.